BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...ATRN-119 and ATRN-212 are in preclinical testing. 2. Chk1 inhibitors. Sierra Oncology Inc. (NASDAQ:SRRA) has SRA737...
...targets in the ATR pathway. Sierra presented two Phase I/II studies of its Chk1 inhibitor SRA737...
...three out of 10 patients had partial responses. The most common adverse events for Sierra's SRA737...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...1 patient; stopped trial to reformulate to allow higher dosing e16517 Sierra Oncology Inc. (NASDAQ:SRRA) SRA737...
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

...Chk1 inhibitor, in Phase I/II testing for solid tumors. Sareum Holdings plc has SRA737 (CCT245737; PNT737...
BioCentury | Oct 10, 2016
Finance

Portfolio POC

...to snatch up an asset. It in-licensed worldwide development and commercialization rights to the fund's CCT245737...
...a royalty. The fund isn't disclosing how much it paid to gain CCT245737 (now called PNT737...
BioCentury | Oct 3, 2016
Company News

CRT Pioneer Fund, ProNAi deal

...The fund granted ProNAi exclusive, worldwide rights to develop and commercialize cancer candidate PNT737 . The...
Items per page:
1 - 5 of 5